To evaluate the pain associated with intravitreal aflibercept injections.
Methods:
The study included 119 patients who received intravitreal aflibercept injection at a single institution. Pain was evaluated by visual analog scale (VAS) immediately after the injection of 2 mg/0.05 mL aflibercept into the vitreous cavity using a 27-G needle. Additional variables including age, sex, indication for the injection, injection site by quadrant (superotemporal or inferotemporal), position during injection (sitting or supine), number of previous intravitreal injections in the study eye, presence of diabetes mellitus or hypertension, and lens status (phakic or pseudophakic) were recorded and assessed with self-reported pain scores.
Results:
Pain scores on the VAS ranged from 9 to 70, with a median of 18. Indications for injection included diabetic macular edema (21.0%), macular edema secondary to central retinal vein occlusion (12.6%), and neovascular age-related macular degeneration (66.38%). Pain did not significantly correlate with any of the recorded variables.
Conclusions:
This is the first series evaluating the pain associated with intravitreal aflibercept injections. We demonstrated that pain associated with intravitreal aflibercept injection is generally mild with low pain scores.
BrownDMKaiserPKMichelsMet al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
2.
RosenfeldPJBrownDMHeierJSet al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
3.
GuntherJBAltaweelMM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol. 2009;54(3):372-400.
4.
CampochiaroPAHeierJSFeinerLet al. BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102-1112.e1.
5.
ElmanMJAielloLPBeckRWet al. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064-1077.e35.
6.
MitchellPBandelloFSchmidt-ErfurthUet al. RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-625.
7.
BoyerDHeierJBrownDMet al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119(5):1024-1032.
8.
KorobelnikJFHolzFGRoiderJet al. GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology. 2014;121(1):202-208.
9.
Schmidt-ErfurthUKaiserPKKorobelnikJFet al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193-201.
10.
BrownDMSchmidt-ErfurthUDoDVet al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology. 2015;122(10):2044-2052.
11.
DvorakHF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20(21):4368-4380.
12.
KimJYYouYSKwonOWKimSH. Sterile inflammation after intravitreal injection of aflibercept in a Korean population. Korean J Ophthalmol. 2015;29(5):325-330.
13.
PanchmatiaHRClementsKMHulbertEet al. Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden. Acta Ophthalmol. 2016;94(5):441-448.
14.
SouiedEHDugelPUFerreiraAHashmonayRLuJKellySP. Severe ocular inflammation following ranibizumab or aflibercept injections for age-related macular degeneration: A retrospective claims database analysis. Ophthalmic Epidemiol. 2016;23(2):71-79.
15.
AmoakuWPearceIBrowningA. Guidelines for intravitreal injections procedure. The Royal College of Ophthalmologists. London. 2009.
16.
CintraLPLucenaLRDa SilvaJACostaRAScottIUJorgeR. Comparative study of analgesic effectiveness using three different anesthetic techniques for intravitreal injection of bevacizumab. Ophthalmic Surg Lasers Imaging. 2009;40(1):13-18.
17.
YauGLJackmanCSHooperPLSheidowTG. Intravitreal injection anesthesia– comparison of different topical agents: a prospective randomized controlled trial. Am J Ophthalmol. 2011;151(2):333-37.
18.
MoisseievERegenbogenMBartfeldYBarakA. Evaluation of pain in intravitreal bevacizumab injections. Curr Eye Res. 2012;37(9):813-7.
19.
RifkinLSchaalS. Factors affecting patients’ pain intensity during in office intravitreal injection procedure. Retina. 2012;32(4):696-700.
20.
GülerMBilginBÇapkınMŞimşekABilakŞ. Assessment of patient pain experience during intravitreal 27-gauge bevacizumab and 30-gauge ranibizumab injection. Korean J Ophthalmol. 2015;29(3):190-4.
21.
van AstenFvan MiddendorpHVerkerkSet al. Are intravitreal injections with ultrathin 33-g needles less painful than the commonly used 30-G needles?Retina. 2015;35(9):1778-85.
22.
ClarkWLBoyerDSHeierJSet al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology. 2016;123(2):330-6.
23.
PrennerJL. Anesthesia for intravitreal injection. Retina. 2011;31(3):433-4.
24.
GambrellJSchaalS. Topical anesthesia for intravitreal injection. Expert Opin Drug Deliv. 2012;9(7):731-3.
MassambaNElluardMAgouneWGuyaderVIngramAPasquierBKnoeriJ. Assessment of ocular pain following ranibizumab intravitreal injection. Acta Ophthalmol. 2015;93(3):e231-2.
27.
SegalOSegal-TrivitzYNemetAYCohenPGeffenNMimouniM. Anxiety levels and perceived pain intensity during intravitreal injections. Acta Ophthalmol. 2016;94(2):203-4.
28.
GoldbergRAShahCPWiegandTWHeierJS. Noninfectious inflammation after intravitreal injection of aflibercept: clinical characteristics and visual outcomes. Am J Ophthalmol. 2014;158(4):733-7.
29.
BalaratnasingamCDhrami-GavaziEMcCannJTGhadialiQFreundKB. Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration. Clin Ophthalmol. 2015;9:2355-71.
30.
HaasPFalkner-RadlerCWimpissingerBMalinaMBinderS. Needle size in intravitreal injections - pain evaluation of a randomized clinical trial. Acta Ophthalmol. 2016;94(2):198-202.
